Blog

The latest thoughts from Medicines Law & Policy partners.

Imagine if health and trade ministers would meet in one room this week

A earlier version of this commentary was published on 28 November 2021 by Barron's. This is a time of missed opportunities. This week, trade ministers...

Price, profit and the Covid-19 health technology pool: The example of remdesivir

We cannot yet know the precise trajectory of the Covid-19 pandemic, nor which therapies or vaccines will eventually prove most effective in its treatment...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

The People vs. AbbVie

Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations

This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...

European Commission Publishes Expert Panel’s Recommendations on High Drug Prices

This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing...

The elephant in the room at the WHO Executive Board

The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

Time to put a stop to the abuse of orphan drug regulation- the latest...

Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...

New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...

The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...